Evidence map›Paper›PMID 21353710›Full record

ReviewTrends in neurosciences2011

Hooked on benzodiazepines: GABAA receptor subtypes and addiction.

Kelly R Tan, Uwe Rudolph, Christian Lüscher

Open access · greenAbstract readReview
In one paragraph

Review in Trends in neurosciences, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 128 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
128citing papers in PubMed, 2 pooled it
8.0field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

128 citing papers in PubMed, 2 syntheses or guidelines pooled it, 363 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Article
  4. Review
  5. Article
  6. Review
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. A Novel Functional Ingredient Derived From a Mixture of Mulberry (Oxidative medicine and cellular longevity · 2026
    Article
  13. Article
  14. Article
  15. Review
  16. Article
  17. Using a rich-lean transition procedure to evaluate putative antianxiety medications.The Journal of pharmacology and experimental therapeutics · 2025
    Article
  18. Article
  19. Article
  20. Article

68 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 2 institutions in 2 countries.

Kelly R TanDepartment of Basic Neurosciences, Medical Faculty, University of Geneva, Geneva, Switzerland.
Uwe Rudolph
Christian Lüscher
University of Geneva · CHHarvard University · US

Funding

Kir 3 Channel Subunits in Drug Abuse with GABAB AgonistsR01DA019022 · NIDA · SALK INSTITUTE FOR BIOLOGICAL STUDIES · PI SLESINGER, PAUL A · 2006 to 2010
$2.3M
NIDA NIH HHS DA019022NIDA NIH HHS R01 DA019022
6 · The paper itself

Abstract

Benzodiazepines are widely used clinically to treat anxiety and insomnia. They also induce muscle relaxation, control epileptic seizures, and can produce amnesia. Moreover, benzodiazepines are often abused after chronic clinical treatment and also for recreational purposes. Within weeks, tolerance to the pharmacological effects can develop as a sign of dependence. In vulnerable individuals with compulsive drug use, addiction will be diagnosed. Here we review recent observations from animal models regarding the cellular and molecular basis that might underlie the addictive properties of benzodiazepines. These data reveal how benzodiazepines, acting through specific GABA(A) receptor subtypes, activate midbrain dopamine neurons, and how this could hijack the mesolimbic reward system. Such findings have important implications for the future design of benzodiazepines with reduced or even absent addiction liability.

Indexed as

Behavior, AddictiveAnimalsAnxiety DisordersBenzodiazepinesDopamineGABA ModulatorsHumansNeuronsProtein SubunitsReceptors, GABA-ARewardSubstance-Related DisordersVentral Tegmental AreaBenzodiazepinesDopamineGABA ModulatorsProtein SubunitsReceptors, GABA-A

Identifiers

PMID21353710
PMCPMC4020178
OpenAlexW1994264681

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.